Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3871-3880

  Murakami, Takayoshi ^a   Tokunaga, Naoyuki ^a   Waku, Toshihiko ^a   Gomi, Shinya ^a   Kagawa, Shunsuke ^a,b   Tanaka, Noriaki ^a   Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; IMMUNIZATION; IMMUNOGENICITY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; FLOW CYTOMETRY; GENES, P53; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2542547503     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0599     Document Type: Article

References (35)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
2. Diebold SS, Cotton M, Koch N, Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001;8:487-93.
3. Fossum S. Lymph-borne dendritic leucocytes do not recirculate but enter the lymph node paracortex to becoming interdigitating cells. Scand J Immunol 1988;27:97-105.
4. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. J Exp Med 1990;171:307-14.
5. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
6. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
8. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-34.
9. Yang S, Kittlesen D, Slingluff CL Jr, et al. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000; 164:4204-11.
10. Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001;12:2203-13.
11. Chikamatsu K, Nakano K, Storkus WJ, et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-8.
12. Eura M, Chikamatsu K, Katsura F, et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:979-86.
13. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
14. Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994;91:3171-5.
15. Arai N, Nomura D, Yokota K. Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol 1986;6:3232-9.
16. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Wash DC) 1984;225:1487-9.
17. Candido KA, Shimizu K, McLaughlin JC, et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 2001;61:228-36.
18. Inaba K, Steinman RM, Pack MW, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175:1157-67.
19. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59:4035-41.
20. Nishimura N, Nishioka Y, Shinohara T, Sone S. Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther 2000;12:333-46.
21. Rea D, Schagen FH, Hoeben RC, et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999;73:10245-53.
22. Morelli AE, Larregina AT, Ganster RW, et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J Virol 2000;74:9617-28.
23. DeLeo AB. p53-based immunotherapy of cancer. Crit Rev Immunol 1998;18:29-35.
24. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer (Phila) 1989;63:496-503.
25. Nakano T, Oka K, Takahashi T, Morita S, Arai T. Roles of Langerhans' cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer (Phila) 1992; 70:2839-44.
26. Tsujitani S, Kakeji Y, Maehara Y, Sugimachi K, Kaibara N. Dendritic cells prevent lymph node metastasis in patients with gastric cancer. In Vivo 1993;7:233-7.
27. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000;11:797-806.
28. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-708.
29. WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene 1997;15:1903-9.
30. Shao J, Fujiwara T, Kadowaki Y, et al. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 2000;19: 726-36.
31. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst (Bethesda) 1999;91:763-71.
32. Waku T, Fujiwara T, Shao J, et al. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J Immunol 2000;165:5884-90.
33. Nikitina EY, Chada S, Muro-Cacho C, et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345-52.
34. Tsujitani S, Okamura T, Baba H, et al. Endoscopic intratumoral injection of OK-432 and Langerhans' cells in patients with gastric carcinoma. Cancer (Phila) 1988;61:1749-53.
35. Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (Phila) 2000;89:2646-54.